Epilogix generates Real-World Evidence (RWE) and develops market access strategy to demonstrate the value of your health technologies. With Epilogix, pharmaceutical and medical device companies gain industry-leading quality insights, delivered by a flexible, globally-distributed team, and a pricing structure that represents substantial savings from services delivered by large Contract Research Organizations (CRO). Epilogix projects have led to over a dozen peer-reviewed journal articles and conference posters since the company’s founding in 2020.

Epilogix was founded by Vernon F. Schabert, Ph.D., an internationally-recognized health economist and pharmacoepidemiologist. He has nearly 30 years of industry experience, leading practices and teams at global health companies such as IQVIA (IMS), Certara (LASER), Merative (Truven, IBM Watson), and Evidera (PPD, Thermo-Fischer). He has led studies of clinical populations in 19 countries around the globe and has earned awards in Europe and the Americas for his innovative research designs and insights. Dr. Schabert has published in therapy areas including solid tumor oncology, hematology, inflammatory and rheumatic disease, CNS and mental health, cardiometabolic disorders, urology, and respiratory disease. As an expert on healthcare data and analytics for medical affairs, health economics, outcomes research, and business analytics, he leads a network of Epilogix Global Advisors in the Americas and Europe that deliver high-quality value and access services with localized expertise.